BTAI BioXcel Therapeutics Inc.

17.49
+0.58  (+3%)
Previous Close 16.91
Open 16.9
Price To Book 9.16
Market Cap 315,432,587
Shares 18,035,025
Volume 186,497
Short Ratio
Av. Daily Volume 274,724
Stock charts supplied by TradingView

NewsSee all news

  1. BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia

     Foundational study with plans to address multiple types of agitation associated with dementia Expands the potential therapeutic use of BXCL501 beyond neuropsychiatric disorders Topline results expected in

  2. BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder

    NEW HAVEN, Conn., Dec. 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics ("BTI" or "Company") (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and

  3. BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor Types

    NEW HAVEN, Conn., Dec. 11, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI" or the "Company") (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify

  4. BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA

    The Company plans to initiate the pivotal studies by year end, with topline data reported mid-2020 The first sublingual, non-invasive acute treatment candidate designed for agitation in neuropsychiatric diseases

  5. BioXcel Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    BioXcel Therapeutics, Inc. ("BTI" or the "Company") (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial announced December 30, 2019 with data due mid-2020.
BXCL501
Schizophrenia - Agitation
Phase 1/2 initial safety data due 1H 2020.
BXCL701 and Keytruda
Neuroendocrine Prostate Cancer (tNEPC)
Phase 1/2 initial data due 1H 2020.
BXCL701
Pancreatic cancer
Phase 1b commencement of enrolment announced January 7, 2020 with data due mid-2020.
BXCL501
Alzheimer’s disease/dementia
Phase 2 trial to be initiated.
BXCL701 and pembrolizumab
Malignant Solid Neoplasm

Latest News

  1. BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia

     Foundational study with plans to address multiple types of agitation associated with dementia Expands the potential therapeutic use of BXCL501 beyond neuropsychiatric disorders Topline results expected in

  2. BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder

    NEW HAVEN, Conn., Dec. 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics ("BTI" or "Company") (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and

  3. BioXcel Therapeutics to Expand Study of BXCL701 into Multiple Advanced Solid Tumor Types

    NEW HAVEN, Conn., Dec. 11, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI" or the "Company") (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify

  4. BioXcel Therapeutics Prepares to Initiate Pivotal Phase 3 Studies with BXCL501 Following Positive End-of-Phase 2 Meeting with FDA

    The Company plans to initiate the pivotal studies by year end, with topline data reported mid-2020 The first sublingual, non-invasive acute treatment candidate designed for agitation in neuropsychiatric diseases

  5. BioXcel Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

    BioXcel Therapeutics, Inc. ("BTI" or the "Company") (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in

  6. BioXcel Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

    Key data readouts expected for BXCL501 in 1H 2020—including results of pivotal Phase 3 trials—with cash position sufficient through completion of studies Phase 1b/2 trial for geriatric dementia/Alzheimer's patients on

  7. BioXcel Therapeutics to Host Third Quarter 2019 Operating and Financial Results Conference Call and Webcast

    BioXcel Therapeutics, Inc. ("BTI" or the "Company") (NASDAQ:BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today

  8. BioXcel Therapeutics Highlights Upcoming Major Milestones

    Clinical results expected 1H 2020 from BXCL501 Phase 3 trial for acute treatment of agitation in Schizophrenia and Bipolar patients Data also expected from BXCL501 Phase 1b in 1H 2020 for acute treatment of agitation in

  9. BioXcel Therapeutics Announces Pricing of Public Offering of Common Stock

    NEW HAVEN, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI" or the "Company") (NASDAQ:BTAI), a clinical-stage biopharmaceutical development company, today announced the pricing of an

  10. BioXcel Therapeutics Announces Proposed Public Offering of Common Stock

    NEW HAVEN, Conn., Sept. 25, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI" or the "Company")  (NASDAQ:BTAI), a clinical-stage biopharmaceutical development company, today announced that it has commenced an

  11. BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital Devices

    Neuropsychiatric patients are vulnerable to multiple agitation episodes; Alzheimer's dementia patients specifically require integrated patient management solutions Expands market potential of BXCL501, if approved,

  12. BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML)

    Expansion of clinical development for BXCL701 program planned in hematological malignancies, beyond solid tumors (Pancreatic and tNEPC) Confirmation and further extension of key findings in Nature Medicine Publication